ZA895909B - Cytotoxic drug conjugates - Google Patents

Cytotoxic drug conjugates

Info

Publication number
ZA895909B
ZA895909B ZA895909A ZA895909A ZA895909B ZA 895909 B ZA895909 B ZA 895909B ZA 895909 A ZA895909 A ZA 895909A ZA 895909 A ZA895909 A ZA 895909A ZA 895909 B ZA895909 B ZA 895909B
Authority
ZA
South Africa
Prior art keywords
drug conjugates
cytotoxic drug
cytotoxic
conjugates
drug
Prior art date
Application number
ZA895909A
Other languages
English (en)
Inventor
David Arthur Johnson
Arthur Johnson David
Bennett Coleman Laguzza
Coleman Laguzza Bennett
William Leonard Scott
Leonard Scott William
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA895909B publication Critical patent/ZA895909B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
ZA895909A 1988-08-08 1989-08-02 Cytotoxic drug conjugates ZA895909B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/229,941 US5028697A (en) 1988-08-08 1988-08-08 Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers

Publications (1)

Publication Number Publication Date
ZA895909B true ZA895909B (en) 1991-04-24

Family

ID=22863313

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA895909A ZA895909B (en) 1988-08-08 1989-08-02 Cytotoxic drug conjugates

Country Status (14)

Country Link
US (1) US5028697A (xx)
EP (1) EP0354729B1 (xx)
JP (1) JPH02256700A (xx)
KR (1) KR900002803A (xx)
CN (1) CN1040204A (xx)
AU (1) AU619328B2 (xx)
DE (1) DE68912232T2 (xx)
DK (1) DK382889A (xx)
HU (1) HU208161B (xx)
IL (1) IL91181A0 (xx)
MX (1) MX165003B (xx)
NZ (1) NZ230199A (xx)
PT (1) PT91371B (xx)
ZA (1) ZA895909B (xx)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5010176A (en) * 1988-11-10 1991-04-23 Eli Lilly And Company Antibody-drug conjugates
US5672683A (en) * 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
ZA914625B (en) * 1990-06-22 1993-02-24 Lilly Co Eli In vivo targeting with bifunctional antibodies
US5272253A (en) * 1991-07-01 1993-12-21 Eli Lilly And Company Cluster conjugates of drugs with antibodies
GR1001459B (el) * 1992-10-08 1993-12-30 Lilly Co Eli Σύμπλεγμα συζυγών φαρμάκων με αντισώματα.
US5382582A (en) * 1993-03-26 1995-01-17 Chan; Carcy L. Methotrexate analogs and methods of using same
US5556623A (en) * 1993-03-30 1996-09-17 Eli Lilly And Company Antibody-drug conjugates
JPH072895A (ja) * 1993-04-28 1995-01-06 Eli Lilly & Co 抗体−薬物複合体
US5773001A (en) * 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US6015555A (en) * 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5712374A (en) * 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5698556A (en) * 1995-06-07 1997-12-16 Chan; Carcy L. Methotrexate analogs and methods of using same
US5714586A (en) * 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US20030119724A1 (en) * 1995-11-22 2003-06-26 Ts`O Paul O.P. Ligands to enhance cellular uptake of biomolecules
CN100406065C (zh) 2000-12-01 2008-07-30 细胞工厂治疗公司 糖基化/半乳糖基化肽、双官能接头和核苷酸单体/多聚体的缀合物以及相关的组合物和使用方法
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
CA2447139C (en) 2001-05-11 2013-11-19 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
WO2004060403A2 (en) * 2003-01-06 2004-07-22 Angiochem Inc. Aprotinin and anglos as carriers across the blood-brain barrier
WO2006031614A2 (en) * 2004-09-10 2006-03-23 Tosk, Inc. Reduced toxicity methotrexate formulations and methods for using the same
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
CN101160403B (zh) * 2005-02-18 2014-08-13 安吉奥开米公司 转运化合物穿过血脑屏障的分子
CA2614687C (en) 2005-07-15 2016-03-22 Angiochem Inc. Use of aprotinin polypeptides as carriers in pharmaceutical conjugates
NZ592293A (en) 2005-11-28 2012-10-26 Verrow Pharmaceuticals Inc Compositions comprising an oligosaccharide such as a cyclodextrin for reducing the nephrotoxicity of other drugs
CN104013956B (zh) 2007-01-25 2018-12-18 达娜-法勃肿瘤研究所公司 抗egfr抗体在治疗egfr突变体介导的疾病中的用途
JP5618549B2 (ja) 2007-03-15 2014-11-05 ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド Ｅｇｆｒ抗体及びｓｒｃ阻害剤を用いる治療方法及び関連製剤
US9365634B2 (en) * 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
ES2609915T3 (es) 2007-08-14 2017-04-25 Ludwig Institute For Cancer Research Ltd. Anticuerpo monoclonal 175 direccionado al receptor de EGF y derivados y usos del mismo
WO2009114325A2 (en) 2008-03-03 2009-09-17 Tosk, Incorporated Methotrexate adjuvants to reduce toxicity and methods for using the same
CN102026667B (zh) * 2008-04-18 2014-06-25 安吉奥开米公司 紫杉醇、紫杉醇类似物或紫杉醇结合物的药物组合物及相关制备方法和用途
MX2011004019A (es) 2008-10-15 2011-06-24 Angiochem Inc Conjugados de etoposido y doxorubicina para entrega de farmacos.
JP2012505637A (ja) 2008-10-15 2012-03-08 アンジオケム，インコーポレーテッド Ｇｌｐ−１アゴニストのコンジュゲート及びその使用
CA2745524C (en) * 2008-12-05 2020-06-09 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
BRPI0922611A2 (pt) 2008-12-17 2018-11-06 Angiochem Inc inibidores de metaloproteína de matriz de membrana tipo 1 e usos dos mesmos
CA2759129C (en) 2009-04-20 2018-12-11 Angiochem Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
MX2012000016A (es) 2009-07-02 2012-03-26 Angiochem Inc Conjugados de peptidos multimericos y sus usos.
KR102316283B1 (ko) 2011-05-16 2021-10-21 젠자임 코포레이션 메토트렉세이트를 이용한 면역 관용의 유도
MX368258B (es) 2013-03-15 2019-09-25 Zymeworks Inc Compuestos citotoxicos y antimitoticos y metodos de uso de los mismos.
CN106255513B (zh) 2013-12-27 2022-01-14 酵活有限公司 用于药物偶联物的含磺酰胺连接系统
IL287645B2 (en) 2014-09-17 2024-04-01 Zymeworks Bc Inc Cytotoxic and anti-mitotic compounds and methods for their use
ES2826827T3 (es) 2015-06-15 2021-05-19 Angiochem Inc Métodos para el tratamiento de carcinomatosis leptomeníngea

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI820020L (fi) * 1981-01-12 1982-07-13 Lilly Industries Ltd Immunoglobulinkonjugater
US4631190A (en) * 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
WO1983000150A1 (en) * 1981-07-02 1983-01-20 Walton, Alan, G. Glycosaminoglycan drug complexes
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
DE3482444D1 (de) * 1983-03-30 1990-07-19 Lilly Industries Ltd Immunoglobulinkonjugate.
US4699784A (en) * 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
GB8610551D0 (en) * 1986-04-30 1986-06-04 Hoffmann La Roche Polypeptide & protein derivatives
CA1330378C (en) * 1986-05-08 1994-06-21 Daniel J. Coughlin Amine derivatives of folic acid analogs
US4997913A (en) * 1986-06-30 1991-03-05 Oncogen pH-sensitive immunoconjugates and methods for their use in tumor therapy
WO1988001513A1 (en) * 1986-08-28 1988-03-10 Teijin Limited Cytocidal antibody complex and process for its preparation
IE63869B1 (en) * 1986-11-06 1995-06-14 Res Dev Foundation Aerosols containing liposomes and method for their preparation
US4918165A (en) * 1987-07-16 1990-04-17 Ophthalmic Research Corporation Mitotic inhibitor and method for preventing posterior lens capsule opacification after extracapsular extraction

Also Published As

Publication number Publication date
HU208161B (en) 1993-08-30
EP0354729A3 (en) 1991-04-17
KR900002803A (ko) 1990-03-23
EP0354729A2 (en) 1990-02-14
PT91371A (pt) 1990-03-08
EP0354729B1 (en) 1994-01-12
DE68912232T2 (de) 1994-05-19
US5028697A (en) 1991-07-02
HUT50850A (en) 1990-03-28
AU619328B2 (en) 1992-01-23
IL91181A0 (en) 1990-03-19
NZ230199A (en) 1991-09-25
DK382889A (da) 1990-02-09
CN1040204A (zh) 1990-03-07
MX165003B (es) 1992-10-13
DK382889D0 (da) 1989-08-04
JPH02256700A (ja) 1990-10-17
AU3933889A (en) 1990-02-08
PT91371B (pt) 1995-05-04
DE68912232D1 (de) 1994-02-24

Similar Documents

Publication Publication Date Title
ZA895909B (en) Cytotoxic drug conjugates
ZA895908B (en) Cytotoxic drug conjugates
EP0366277A3 (en) Pharmaceutical formulations
EP0335545A3 (en) Pharmaceutical formulations for parenteral use
GB9410236D0 (en) Cytotoxic drug therapy
ZA892315B (en) Pharmaceutical formulations for parenteral use
HUT53126A (en) Antibody medicament conjugates
GB2228922B (en) Packaging drugs
EP0299057A4 (en) INCREASING THE POWER OF CYTOTOXIC CONJUGATES.
EP0443027A4 (en) Drug composition
ZA899948B (en) Pharmaceutical preparation
IE892533L (en) Cytotoxic drug conjugates
IE892534L (en) Cytotoxic drug conjugates
ZA893463B (en) Drug adsorbates
GB8901158D0 (en) Administering drugs
IE883489L (en) Drug-monoclonalantibody conjugates
IL92583A0 (en) Tolerogenic immunoglobulin-protein conjugates
GB8820343D0 (en) Pharmaceutical formulations
GB8810733D0 (en) Pharmaceutical formulations
GB8820272D0 (en) Pharmaceutical formulations
GB8820271D0 (en) Pharmaceutical formulations
GB8820175D0 (en) Pharmaceutical formulations
GB8816609D0 (en) Pharmaceutical formulations
GB8813402D0 (en) Pharmaceutical formulations
GB8820273D0 (en) Pharmaceutical formulations